Form 4: Alzamend Neuro Director Sells All Directly Held Shares

Alzamend Neuro Director William B. Horne sold 3,333 shares of common stock at $2.1178 per share, reducing his direct beneficial ownership to zero.

Summary

• Director William B. Horne of Alzamend Neuro, Inc. (ALZN) reported the sale of 3,333 shares of common stock.
• The transaction occurred on December 19, 2025, at a price of $2.1178 per share.
• Following this sale, Mr. Horne's direct beneficial ownership of Alzamend Neuro common stock is 0 shares.
• The sale was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.

Sentiment

Score: 3

Explanation: The sale of all directly held common stock by a director, even under a 10b5-1 plan, typically signals a lack of confidence or a personal financial decision that could be viewed negatively by investors.

Negatives

• Director William B. Horne sold all 3,333 directly owned shares of Alzamend Neuro common stock.
• The sale reduces the director's direct beneficial ownership to zero, which can be perceived as a lack of confidence.

Risks

• The complete divestment of directly held common stock by a director, even under a 10b5-1 plan, could be interpreted by the market as a negative signal regarding the company's future prospects or valuation.

Future Outlook

This filing does not contain any forward-looking statements or guidance from the company.

Industry Context

Insider transactions, such as sales by directors, are closely watched by investors as they can provide insights into management's perception of the company's value. While sales under a 10b5-1 plan are pre-scheduled and not necessarily indicative of immediate market timing, a complete divestment by a director can still be a notable event within the industry context.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the director's complete divestment of directly held shares as a negative indicator, potentially impacting investor sentiment and the company's stock price.

Key Dates

Recommendation

The sale of all directly held common stock by a director, even under a pre-arranged 10b5-1 plan, can be interpreted as a lack of conviction in the company's future performance. While not necessarily indicative of immediate distress, it warrants caution and further investigation into the company's fundamentals before making investment decisions. A 'hold' recommendation reflects this cautious stance.

Keywords

Alzamend Neuro, ALZN, insider trading, Form 4, director sale, stock transaction, William B. Horne, 10b5-1 plan